Table 6.

Mutations detected in the lung adenocarcinoma with compound EGFR mutation.

Rand No.	ALK	BCL2L11	BRAF	ERBB2	FGFR1	KRAS	MET	NRAS	PIK3CA	PTEN	ROS1	RET
E0001												c.2071G>A
E0012
E0048
E0092											c.5704G>A
E0113	Rearrangement*, c.3755C>T		c.1760A>T		c.2275G>A, c.1417C>T, c.1391C>T, c.1382C>T,		c.2610G>A, c.2612G>A, c.3670G>A	c.235C>T, c.38G>A, c.31G>A, c.29G>A, c.28G>A,			c.5770G>A, c.5741C>T, c.5587A>C, c.5572C>T
E0140			c.1766C>T		c.2293C>T, c.1490C>T, c.487G>A	c.85G>A	c.2327G>A, c.2389G>A	c.203G>A, c.38G>A				c.2071G>A
E0154											c.5704G>A
E0170
E0176
E0214		Int 2 del**
E0217	c.3808G>A, c.3781G>A		c.1822C>T, c.1793C>T		c.2209G>C, c.1505G>A, c.1495G>A, c.1489C>T, c.1426C>T, c.1346C>T	c.160G>A, c.91G>A, c.35G>A*	c.1231G>A, c.1268C>T, c.1492C>T, c.2119C>T, c.2161G>A, c.2336C>T, c.2395G>A, c.3512C>T, c.3584C>T, c.3683G>A, c.3745G>A	c.201G>A, c.169G>A, c.50G>A, c.25G>A	c.1656G>A	c.724G>A, c.754G>A	c.5572C>T, c.5291G>A	c.2143C>T
E0228
E0231
E0235	c.3821C>T,		c.1798G>A, c.1753C>T	c.2499G>A			c.2191C>T, c.2324G>A, c.2339G>A, c.3322G>A, c.3395G>A, c.3687G>A	c.239G>A, c.176C>T, c.32C>T	c.3104C>T	c.653G>A	c.5770G>A, c.5602G>A, c.5333G>A, c.5326G>C
E0254

^*Actionable mutations (19).

^**BCL2L11 intron 2 deletion mutant (20).

^†No mutation was detected in AKT1, DDR2, and MAP2K1.